Defect Bash - Literature Review
Defect bash is a co-located testing session performed by a group of people. We performed a systematic review of the academic and grey literature, i.e. informally published writings, of the defect bash. Altogether, we found 44 items (17 academic and 27 grey literature sources) that were identified useful for the review. Based on the review the definition of defect bash is presented, benefits and limitations of using defect bash are given. Finally, the process of doing defect bash is outlined. This review provides initial understanding on how defect bash could be useful in achieving the software quality and lays foundation for further academic studies of this topic.
The 10-Minute Test Plan
The lowly test plan is perhaps the least appreciated of all supporting (read: noncode) software development artifacts. All projects need one, but few engineers appreciate their existence. So it's important to spend no more time than is absolutely necessary in the creation, care, and feeding of the test plan. Ten minutes, to be precise.
Antitumor activities of (2"R)-4'-O-tetrahydropyranyl-adriamycin (THP) and its combination with other antitumor agents on murine tumors.
(2''R)-4'-O-Tetrahydropyranyladriamycin (THP) is a new derivative of doxorubicin (adriamycin, ADM). The concentrations of THP and ADM required to inhibit by 50% the growth of a cultured L1210 cells was 0.003 microgram/ml and 0.016 microgram/ml, respectively. Various therapeutic designs of combinations of THP with other antitumor agents were investigated in vivo using the L1210 murine leukemia. The combination of THP with cytosine arabinoside (Ara-C), cyclocytidine hydrochloride (Cyclo-C), 6-mercaptopurine (6-MP) and cyclophosphamide (EX) showed a great effectiveness following daily intraperitoneal treatment from days 1 to 10. High therapeutic effects were also obtained with the combinations of THP with Ara-C, Cyclo-C, vincristine (VCR) and EX following intravenous combination therapy one day following implantation of L1210 leukemia. Schedule dependency and its therapeutic efficacy of THP were examined. THP showed almost the same antitumor activity on the solid-type sarcoma-180 or solid-type Ehrlich carcinoma as ADM by intraperitoneal or intravenous treatment. THP showed some superior activity to ADM in the advanced stage of L1210 leukemia. High antitumor activity of THP on murine leukemia L1210 has been reported by Tsuruo et al. (Cancer Res. 42: 1462-1467, 1982) and was also confirmed. THP gave many mice cures, especially in the intravenous treatment.